Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection.
about
Era of direct acting antivirals in chronic hepatitis C: Who will benefit?Human Immunodeficiency Virus Type 1-Hepatitis C Virus Coinfection: Intraindividual Comparison of Cellular Immune Responses against Two Persistent VirusesThe natural history of hepatitis C virus (HCV) infection.Factors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern ChinaHighly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infectionHigh prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in ChinaHuman immunodeficiency virus and liver disease forum 2010: conference proceedingsNatural history of chronic hepatitis CEligibility of persons who inject drugs for treatment of hepatitis C virus infection.MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates.Acute kidney injury in a diabetic haemophiliac: one step at a time.Hepatitis C virus infection in the human immunodeficiency virus infected patient.Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia.The natural history and antiviral treatment of hepatitis C in haemophilia.Liver transplantation in HCV/HIV positive patients.HIV infection increases HCV-induced hepatocyte apoptosis.Hepatitis C and human immunodeficiency virus infection.Reduced type 1 and type 2 cytokines in antiviral memory T helper function among women coinfected with HIV and HCV.Characteristics of HCV co-infection among HIV infected individuals from an area with high risk of blood-borne infections in central China.Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and designLiver transplant outcomes in HIV+ haemophilic men.The history of the "natural history" of hepatitis C (1968-2009).Management of chronic hepatitis C.Hepatitis C in haemophilia: lights and shadows.Evidence of distinct populations of hepatitis C virus in the liver and plasma of patients co-infected with HIV and HCV.Treatment of hepatitis C in HIV-coinfected patients.Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulationHCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?Clinical Liver Disease Progression Among Hepatitis C-Infected Drug Users With CD4 Cell Count Less Than 200 Cells/mm(3) Is More Pronounced Among Women Than Men.Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?Legal, financial, and public health consequences of transfusion-transmitted hepatitis C virus in persons with haemophilia.Management complexities of HIV/hepatitis C virus coinfection in the twenty-first centuryLow rates of sustained virologic response with peginterferon plus ribavirin for chronic hepatitis C virus infection in HIV infected patients in Rio de Janeiro, Brazil.Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection.Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies.Liver transplantation in the haemophilia patient.Liver transplantation in the haemophilia patient.The aging patient with hemophilia.Role of GB virus C in modulating HIV disease
P2860
Q26777506-7DC54FD4-6AA5-4D06-A4CC-4F5E843AC824Q27472844-79E15A57-E061-4390-B22A-CDB77BE89A45Q27473116-1BE07EA1-85F7-43AF-8DED-F3276024A1C6Q27488825-8C3ED274-33AC-4D87-9EF0-C33CAD4557D1Q27489103-DE5F25F7-5AB6-4B11-9BE7-924279D24CDDQ28474105-3BD6AAE8-E19A-4754-B301-D74F8BFBABD4Q28674930-96435A2D-6DBA-482A-9FC2-1FE92BCFE041Q29620673-A60F761B-C59E-4CC0-A84E-7EA9107544C4Q30429470-D4493696-3451-480B-8034-91EDD355CFC3Q30433644-8BA5AFED-C034-4EA7-91E7-B4392D154939Q33629093-28504127-8063-45BA-8B1B-243C356796E1Q34168504-311FD31C-13CA-4C43-B2EC-B39CC0C81856Q34345002-9DD898BC-6B8C-4396-B598-B8175323FDADQ34637021-932DF33F-4C6D-4C9E-9DF0-3EFE0B97D01CQ34640985-33361C59-5976-4DC8-9A87-B6762539DC15Q34699457-262621A2-3297-4FEA-945F-5BE53F8C4483Q34984125-81C6F30F-3C3B-4D98-A804-1B6ABE581C47Q35079621-25532A97-FC38-4F3B-B0F4-7DF84BB5D943Q35141727-384F181B-8D3F-474B-9363-A64C8B2B81C3Q35150425-92AAE6AA-75BF-4DC8-A000-CE1C7EB492B7Q35153955-49A0EF15-C26A-42E4-B736-D661FA4DBA55Q35216592-9E97F227-95D4-4DE8-9A57-02F07BA06735Q35522138-BEDD7650-054F-43FF-99F5-674274325579Q35915753-E52B6AEF-1DB5-49C3-8BBE-8409A85E0F61Q36034450-5E92E71E-E161-495D-8FEB-49AC103D4AB5Q36409500-AD3D65C3-A49A-49D9-B1EA-764AFDA479DCQ36444618-FE2F5AB9-8AA8-4441-8D7F-D398EC0859ABQ36479368-7357C33E-2422-4FD1-A699-E768C38634CEQ36650557-AC0E8E21-0057-4D68-AF5E-F9535F75103FQ36746459-91FF3C0B-E85F-4E79-B081-FD2766AA28D9Q36903919-7B314584-C72C-4FA7-BEB1-89D28D744C71Q36995854-59980F40-EC54-450C-813D-CCFA07C29856Q36997245-E8865F26-42E9-4392-AFD6-A80DF660BA30Q37122490-6B9A1DC9-9D73-4555-AC73-53B1B6BA3CC4Q37326067-C4AFF7C7-12EC-434B-A4B5-E9309AC80EF7Q37355850-9D31BCAD-8476-42B0-8A44-763168BE3D21Q37866367-A6B28262-0DCA-4E09-90EC-4036690DDCD4Q37919966-42FACE3F-7B76-4F8C-912B-C94B39662C34Q37995101-29E8EADC-544F-4334-91CE-53A4C85F22F0Q38018981-3B757E6E-A91D-4F7C-BE6B-A949C6C69F1F
P2860
Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Impact of human immunodeficien ...... d hepatitis C virus infection.
@ast
Impact of human immunodeficien ...... d hepatitis C virus infection.
@en
type
label
Impact of human immunodeficien ...... d hepatitis C virus infection.
@ast
Impact of human immunodeficien ...... d hepatitis C virus infection.
@en
prefLabel
Impact of human immunodeficien ...... d hepatitis C virus infection.
@ast
Impact of human immunodeficien ...... d hepatitis C virus infection.
@en
P356
P1476
Impact of human immunodeficien ...... d hepatitis C virus infection.
@en
P2093
P304
P356
10.1086/319273
P407
P577
2001-03-01T00:00:00Z